search

Active clinical trials for "Lung Neoplasms"

Results 1561-1570 of 6521

Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients...

Elderly PatientsMetastatic Lung Cancer

Lung cancer is the cancer with the highest morbidity and mortality among men in the world. The proportion of elderly lung cancer patients in the global lung cancer population is steadily increasing, at the same time, it is also the age group with the highest lung cancer mortality, but there is little evidence for treatment of elderly lung cancer patients. In this study, the investigators set the definition of the elderly to 65 years and older. The progression-free survival (PFS) and overall survival (OS) of immunotherapy plus chemotherapy were higher than those of chemotherapy alone, which established the dominant position of dual-drug chemotherapy combined with immunotherapy. Studies showed that elderly patients benefit from immunotherapy. It is controversial whether elderly advanced non-small-cell-lung-cancer (NSCLC) patients should receive single-drug chemotherapy or dual-drug chemotherapy. MILES-3 and MILES-4 studies show that in the advanced NSCLC elderly patients, combined with cisplatin on the basis of single drug chemotherapy can not significantly prolong OS, and can not improve the overall health status of patients. Based on the results of this study, single drug chemotherapy is still the preferred first-line regimen. Another study showed that carboplatin combined with paclitaxel had longer OS than gemcitabine or vinorelbine alone in elderly patients with advanced NSCLC with a performance status (PS) score of less than 2. In the era of immunotherapy, it is not clear whether single-drug chemotherapy combined with immunotherapy can achieve the same therapeutic effect as dual-drug chemotherapy combined with immunotherapy. Therefore, the purpose of this study is to investigate the efficacy and safety of single-drug chemotherapy plus immunotherapy in elderly metastatic NSCLC patients.

Not yet recruiting16 enrollment criteria

Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

Small Cell Lung CancerAngiogenesis1 more

To evaluate the clinical efficacy and safety of surufatinib combined with irinotecan in the second line treatment of small cell lung cancer.

Not yet recruiting31 enrollment criteria

Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC

Lung CancerStage III Lung Cancer1 more

Multi-center observational clinical study to evaluate the application value of ctDNA monitoring in efficacy assessment and relapse prediction in patients diagnosed with unresectable, locally advanced NSCLC receiving CRT with or without durvalumab maintenance treatment.

Recruiting5 enrollment criteria

Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small Cell Lung Cancer

Lung Cancer

This prospective observational study was designed to evaluate the safety and efficacy of PD-1/PD-L1 inhibitors in combination with statins compared with treatment with PD-1/PD-L1 inhibitors alone in advanced NSCLC patients. Participants will receive either immunotherapy + statin or immunotherapy until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until persistent radiographic PD or symptomatic deterioration.

Recruiting16 enrollment criteria

A Safety Study of 212Pb-Pentixather Radioligand Therapy

Carcinoid Tumor LungNeuroendocrine Tumor of the Lung2 more

This is a first-in-human clinical trial evaluating the safety of an alpha-radiation treatment (Lead-212 labelled Pentixather) in patients who have been diagnosed with, and previously treated, for atypical carcinoid lesions of the lung.

Not yet recruiting16 enrollment criteria

A Phase Ⅱ Clinical Study of Combination Therapy of SKB264 in Patients With Advanced or Metastatic...

Non-small Cell Lung Cancer

The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB264 in combination with KL-A167 with or without chemotherapy with advanced or metastatic non-small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.

Not yet recruiting24 enrollment criteria

Patient's Whole Process Follow-up Management(HOPE-1)

Locally Advanced Non-Small Cell Lung CancerMetastatic NSCLC

Our project is going to explore whether management and follow-up of locally advanced/metastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.

Recruiting12 enrollment criteria

Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer

Non-Small Cell Carcinoma of LungTNM Stage 4

The purpose of this study is to provide high quality oncology services to patients with inoperable Non-Small Cell Lung Cancer (NSCLC) in Greece. These services will be based on 3 pillars: Clinical: personalized treatment will be administered and its effectiveness and safety will be recorded and evaluated. Molecular: the gene footprint of each patient at the beginning of his treatment, the molecular identity of his tumor will be analyzed and recorded based on analysis with modern Next Generation Sequencing (NGS) techniques. Digital: Patients will have access to the digital platform where they will record the adverse reactions they will face during their treatment.

Recruiting9 enrollment criteria

An Observational Study to Assess the Effectiveness and Safety of Cemiplimab in Patients With Advanced...

Non-small Cell Lung Cancer

Primary Objective: Describe the overall survival rate (OS) rate in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice. Secondary Objectives: To describe the following in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice: Objective response rate (ORR) Time to response (TTR) Time to progression Time to first subsequent anti-NSCLC treatment (TTST) Duration of response (DoR) Progression-free Survival (PFS) Incidence and severity of adverse events (AEs) in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice

Recruiting14 enrollment criteria

A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal...

Advanced Rectal CancerLiver Metastasis2 more

Although patients with locally advanced rectal cancer and resectable liver/pulmonary metastasis could benefit from surgery resection, these patients still have a poorer prognosis compared to those without distal metastasis. Based on previous studies, there is no confirmation of whether these patients could benefit from preoperative immunotherapy combined with conventional chemoradiotherapy. This study proposes a combination therapy, preoperative short-course radiotherapy followed by neoadjuvant chemotherapy and anti-PD-1 immunotherapy, for microsatellite-stable patients with locally advanced rectal cancer and resectable liver/pulmonary metastasis, to assess its impact on tumor retreat, decline of postoperative metastasis and recurrence, and the disease-free survival and overall survival of patients. Besides, this study will provide high-level medical evidence for future clinical treatment of patients with advanced rectal cancer.

Not yet recruiting58 enrollment criteria
1...156157158...653

Need Help? Contact our team!


We'll reach out to this number within 24 hrs